
    
      The schedule of treatment includes vinorelbine (30 mg/m2 on days 1 & 8 every 21 days) and
      trastuzumab (8 mg/kg on day 1 and then 6 mg/kg every 21 days). Vinorelbine is planned for
      maximum 9 cycles, while trastuzumab can be continued until progression. This study is a
      single-stage phase 2 design, and patients eligible for response evaluation are required.
    
  